When evaluating the safety and efficacy of entrectinib for ROS1 fusion-positive NSCLC, Drilon et al. reported that 94% of patients experienced ≥1 treatment-related adverse event (TRAE). This evidence concerns the gene ROS1 and non-small cell lung carcinoma.